Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Csep1P protein from Campylobacter concisus induces a chemokine-dominant inflammatory state in macrophages and enhances proinflammatory response to gut bacteria.

PLoS pathogens·2026
Same author

Multi-Cohort Exploration of Repetitive Element Transcription and DNA Methylation in Human Steatotic Liver Disease.

International journal of molecular sciences·2025
Same author

Age-Dependent Variations in the Distribution of <i>Aeromonas</i> Species in Human Enteric Infections.

Pathogens (Basel, Switzerland)·2025
Same author

Human macrophage response to the emerging enteric pathogen <i>Aeromonas veronii</i>: Inflammation, apoptosis, and downregulation of histones.

Virulence·2024
Same author

Epidural steroid injection technique.

Techniques in vascular and interventional radiology·2024
Same author

Oral-gut microbiome interactions in advanced cirrhosis: characterisation of pathogenic enterotypes and salivatypes, virulence factors and antimicrobial resistance.

Journal of hepatology·2024

Related Experiment Video

Updated: Jul 5, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Perspectives on liver failure: past and future.

Stephen M Riordan1, Roger Williams

  • 1Gastrointestinal and Liver Unit, The Prince of Wales Hospital and University of New South Wales, Sydney, Australia.

Seminars in Liver Disease
|May 3, 2008
PubMed
Summary

Acute liver failure (ALF) treatment has improved, but outcomes have plateaued. New research into ALF

Area of Science:

  • Hepatology and Intensive Care Medicine
  • Regenerative Medicine
  • Molecular Biology

Background:

  • Acute liver failure (ALF) is a severe condition with historically high mortality rates.
  • Significant advancements in intensive care units and extracorporeal liver support devices have improved survival.
  • However, survival rates have plateaued, necessitating further understanding and novel therapeutic strategies.

Purpose of the Study:

  • To review the current understanding of ALF management and identify areas for future research.
  • To explore the potential of targeting molecular pathways involved in hepatocyte cell death for therapeutic benefit.
  • To address the challenge of reducing liver cell death while preserving regenerative capacity.

Main Methods:

  • Review of clinical observations and trials in specialized ALF intensive care units.

More Related Videos

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Extended 78&#37; Hepatectomy in a Mouse Surgical Model
05:25

Extended 78% Hepatectomy in a Mouse Surgical Model

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Jul 5, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Extended 78&#37; Hepatectomy in a Mouse Surgical Model
05:25

Extended 78% Hepatectomy in a Mouse Surgical Model

Published on: May 24, 2024

  • Analysis of current knowledge on molecular mechanisms of hepatocyte cell death in ALF.
  • Discussion of therapeutic strategies targeting cell death pathways and liver regeneration.

    • Main Results:

    • Survival rates for ALF have dramatically increased from nearly 100% to current levels, largely due to improved critical care.
    • A significant proportion of ALF cases lack identifiable etiologies, hindering targeted treatment.
    • Understanding molecular pathways of hepatocyte death offers potential for future therapeutic interventions.

    Conclusions:

    • Despite improved survival, ALF outcomes require further advancement, possibly through novel therapeutic targets.
    • Intervening in molecular cell death pathways presents a promising avenue, particularly in early disease stages.
    • Balancing the inhibition of hepatocellular death with the preservation of liver regeneration is a critical challenge for future ALF therapies.